Strategic Growth QbD Group has a track record of rapid expansion through acquisitions (Azierta, Turnstone Communications, BioVox, Michor Consulting, EUDRAC) which signals ongoing capacity to handle larger client engagements and broaden service offerings. This presents sales opportunities with mid-to-large pharma, biotech, and MedTech firms seeking integrated life sciences support across regulatory, clinical, and market access functions.

Lifecycle Expertise With capabilities spanning from early-stage innovation to market access and lifecycle management, QbD Group positions itself as a one-stop partner for companies aiming to accelerate development and maintain post-market compliance. Target potential clients pushing for end-to-end support, especially those navigating complex EU regulatory pathways via Gateway to Europe.

Regulatory & Quality Focus Core strengths in regulatory, clinical, and quality assurance offer cross-sell opportunities to biotechs and MedTech firms preparing for submissions, inspections, or quality improvements. Prospects include companies needing robust quality systems and lifecycle governance to de-risk submissions and manufacturing operations.

Europe Gateway Positioning as a gateway to Europe is a compelling value prop for non-EU companies seeking market access. Target international life sciences players looking to enter or expand in Europe, offering a clear route to regulatory compliance, local counsel, and market strategy.

Digital & Marketing Readiness QbD Group leverages a modern tech stack and has demonstrated activity in communications and public affairs through acquired marketing-focused units. This suggests opportunities to upsell enhanced scientific communications, investor materials, and regulatory storytelling services to clients needing strategic messaging for submissions, launches, or funding rounds.